A crowded field of next-generation contenders is also pushing forward: Amgen's AMG 133, Roche's GLP-1/GIP co-agonists, AstraZeneca's cotadutide, and Phase 2 candidates like HRS9531 and MariTide (a GLP-1 agonists plus GIP antagonist) are all showing early promise in obesity treatment
We couldnt understand this, which is why we looked as many different ways as we could to see if this was a really robust observation, she said
3 The takeaway: Behavior change matters to people on GLP-1s, and the Noom app continues to be associated with stronger real-world GLP-1 outcomes Taken together, these findings tell a clear story: people who pair GLP-1 medication with consistent engagement in the Noom app see more success at weight loss, and, independently, they stay with the program longer
In this article, we'll explore the v
warm compresses after injection promote healing by boosting local circulation